Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990–2023: a Global Burden of Disease study

Abstract

Chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD), asthma, pneumoconiosis, interstitial lung disease (ILD) and pulmonary sarcoidosis, are major global causes of mortality and morbidity. Although the COVID-19 pandemic has influenced acute respiratory health, its impact on chronic respiratory conditions remains unclear. We estimated the global, regional and national burden of chronic respiratory diseases from 1990 to 2023, including risk factors, and evaluated how these burdens have shifted during the COVID-19 pandemic using the Global Burden of Disease Study 2023. In 2023, chronic respiratory diseases accounted for 569.2 million (95% uncertainty interval (UI), 508.8–639.8) cases and 4.2 million (3.6–5.1) deaths. The age-standardized death rate declined by 25.7% globally from 1990 to 2023 despite an increase in ILD and pulmonary sarcoidosis. Mortality declined in younger males, especially for asthma, whereas older adults experienced a rise in ILD and pulmonary sarcoidosis. Smoking was the primary risk factor for COPD, whereas high body mass index and silica exposure were key risk factors for asthma and pneumoconiosis. During the pandemic, the incidence of chronic respiratory diseases increased modestly, but the decline in mortality rates became more pronounced, highlighting the need for sustained global attention and action to address their long-term burden.

This is a preview of subscription content, access via your institution

Access options

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: World map of age-standardized prevalence rates for COPD, asthma, pneumoconiosis, ILD and pulmonary sarcoidosis in 2023.
Fig. 2: World map of age-standardized death rates for COPD, asthma, pneumoconiosis, ILD and pulmonary sarcoidosis in 2023.
Fig. 3: Global age-sex-specific COPD, asthma, pneumoconiosis, ILD and pulmonary sarcoidosis death rates, 1990–2023.
Fig. 4: AAPC of age-standardized incidence and death rates for COPD, asthma, pneumoconiosis, ILD and pulmonary sarcoidosis by GBD region during the pre-COVID-19 (2010–2019) and pandemic period (2020–2023).
Fig. 5: Global and regional distribution of age-standardized DALY rates for COPD, asthma, and pneumoconiosis by risk factor in males and females, 2023.

Similar content being viewed by others

Data availability

The findings from this study were produced using data available in public online repositories or in the published literature, as well as data that are publicly available from the data provider under certain conditions. Details on data sources can be found on the GHDx website, including information about the data provider and links to where the data can be accessed (where available). Citations and metadata for all input sources used in this analysis are available for download at https://ghdx.healthdata.org/gbd-2023/sources. Most GBD data can be accessed directly upon visiting the GHDx website, and some datasets may require agreement to a data use policy before download. Access is typically granted immediately upon completion of these steps.

Code availability

Our study follows the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER; Supplementary Table 4). All code used for this analysis is publicly available online at https://github.com/CenterForDH/Chronic-respiratory-diseases.git.

References

  1. Cho, M. H. et al. A genome-wide association study of emphysema and airway quantitative imaging phenotypes. Am. J. Respir. Crit. Care Med. 192, 559–569 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Soriano, J. B. et al. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir. Med. 8, 585–596 (2020).

    Google Scholar 

  3. Momtazmanesh, S. et al. Global burden of chronic respiratory diseases and risk factors, 1990-2019: an update from the Global Burden of Disease Study 2019. eClinicalMedicine 59, 101936 (2023).

    Google Scholar 

  4. Hay, S. I. et al. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 406, 1873–1922 (2025).

    Google Scholar 

  5. Bousquet, J., Dahl, R. & Khaltaev, N. Global Alliance against Chronic Respiratory Diseases. Eur. Respir. J. 29, 233–239 (2007.

    CAS  PubMed  Google Scholar 

  6. Greene, C. M. & Abdulkadir, M. Global respiratory health priorities at the beginning of the 21st century. Eur. Respir. Rev. 33, 230205 (2024).

    PubMed  PubMed Central  Google Scholar 

  7. Bender, R. G. et al. Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Infect. Dis. 24, 974–1002 (2024).

    Google Scholar 

  8. Ledesma, J. R. et al. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Infect. Dis. 24, 698–725 (2024).

    Google Scholar 

  9. Gravely, S. et al. Implementation of key demand-reduction measures of the WHO Framework Convention on Tobacco Control and change in smoking prevalence in 126 countries: an association study. Lancet Public Health 2, e166–e174 (2017).

    PubMed  Google Scholar 

  10. Reddel, H. K. et al. Global Initiative for Asthma Strategy 2021: Executive Summary and rationale for key changes. Am. J. Respir. Crit. Care Med. 205, 17–35 (2022).

    PubMed  Google Scholar 

  11. Ferguson, G. T. et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir. Med. 6, 747–758 (2018).

    CAS  PubMed  Google Scholar 

  12. Martinez, F. J. et al. Idiopathic pulmonary fibrosis. Nat. Rev. Dis. Primers 3, 17074 (2017).

    PubMed  Google Scholar 

  13. Akhter, N. & Rizvi, N. Interstitial lung diseases misdiagnosed as tuberculosis. Eur. Respir. J. 50, PA2716 (2018).

    Google Scholar 

  14. Gerke, A. K., Judson, M. A., Cozier, Y. C., Culver, D. A. & Koth, L. L. Disease burden and variability in sarcoidosis. Ann. Am. Thorac. Soc. 14, S421–S428 (2017).

    PubMed  PubMed Central  Google Scholar 

  15. Schaub, B., Lauener, R. & von Mutius, E. The many faces of the hygiene hypothesis. J. Allergy Clin. Immunol. 117, 969–977 (2006).

    PubMed  Google Scholar 

  16. Spagnolo, P. & Schwartz, D. A. Genetic predisposition to sarcoidosis: another brick in the wall. Eur. Respir. J. 41, 778–780 (2013).

    CAS  PubMed  Google Scholar 

  17. Chowdhury, N. U., Guntur, V. P., Newcomb, D. C. & Wechsler, M. E. Sex and gender in asthma. Eur. Respir. Rev. 30, 210067 (2021).

    PubMed  PubMed Central  Google Scholar 

  18. Zein, J. G. et al. Benefits of airway androgen receptor expression in human asthma. Am. J. Respir. Crit. Care Med. 204, 285–293 (2021).

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Azoulay, E. et al. Diagnosis of severe respiratory infections in immunocompromised patients. Intensive Care Med. 46, 298–314 (2020).

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Guillo, E. et al. COVID-19 pneumonia: diagnostic and prognostic role of CT based on a retrospective analysis of 214 consecutive patients from Paris, France. Eur. J. Radiol. 131, 109209 (2020).

    PubMed  PubMed Central  Google Scholar 

  21. Kim, M. S. et al. Long-term autoimmune inflammatory rheumatic outcomes of COVID-19. Ann. Intern. Med. 177, 291–302 (2024).

    PubMed  Google Scholar 

  22. Alqahtani, J. S. et al. Reduction in hospitalised COPD exacerbations during COVID-19: a systematic review and meta-analysis. PLoS ONE 16, e0255659 (2021).

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Sykes, D. L., Faruqi, S., Holdsworth, L. & Crooks, M. G. Impact of COVID-19 on COPD and asthma admissions, and the pandemic from a patient’s perspective. ERJ Open Res. 7, 00822–2020 (2021).

    PubMed  PubMed Central  Google Scholar 

  24. Brooks, J. T. & Butler, J. C. Effectiveness of mask wearing to control community spread of SARS-CoV-2. JAMA 325, 998–999 (2021).

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Lee, H. et al. Interstitial lung disease increases susceptibility to and severity of COVID-19. Eur. Respir. J. 58, 2004125 (2021).

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Choi, Y. et al. Acute and post-acute respiratory complications of SARS-CoV-2 infection: population-based cohort study in South Korea and Japan. Nat. Commun. 15, 4499 (2024).

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Oh, J. et al. Incident allergic diseases in post-COVID-19 condition: multinational cohort studies from South Korea, Japan and the UK. Nat. Commun. 15, 2830 (2024).

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Izquierdo, J. L. et al. The impact of COVID-19 on patients with asthma. Eur. Respir. J. 57, 2003142 (2021).

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Yang, J. M. et al. Allergic disorders and susceptibility to and severity of COVID-19: a nationwide cohort study. J. Allergy Clin. Immunol. 146, 790–798 (2020).

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Aveyard, P. et al. Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study. Lancet Respir. Med. 9, 909–923 (2021).

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Boehm, A. et al. Assessing global COPD awareness with Google Trends. Eur. Respir. J. 53, 1900351 (2019).

    PubMed  Google Scholar 

  32. Kennedy, B. K. et al. Geroscience: linking aging to chronic disease. Cell 159, 709–713 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Balmes, J. R. Household air pollution from domestic combustion of solid fuels and health. J. Allergy Clin. Immunol. 143, 1979–1987 (2019).

    CAS  PubMed  Google Scholar 

  34. Ramirez, C. et al. Achieving Nepal’s clean cooking ambitions: an open source and geospatial cost–benefit analysis. Lancet Planet Health 8, e754–e765 (2024).

    PubMed  Google Scholar 

  35. Alupo, P. et al. Overcoming challenges of managing chronic obstructive pulmonary disease in low- and middle-income countries. Expert Rev. Respir. Med. 18, 873–882 (2024).

    CAS  PubMed  Google Scholar 

  36. Naghavi, M. et al. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 406, 1811–1872 (2025).

    Google Scholar 

  37. Harari, S. et al. Fibrotic interstitial lung diseases and air pollution: a systematic literature review. Eur. Respir. Rev. 29, 200093 (2020).

    PubMed  PubMed Central  Google Scholar 

  38. Brauer, M. et al. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 403, 2162–2203 (2024).

    Google Scholar 

  39. Kim, M. S. et al. Global burden of peripheral artery disease and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Glob. Health 11, e1553–e1565 (2023).

    Google Scholar 

  40. Pérez, A., Valencia, S., Jani, P. P. & Harrell, M. B. Use of electronic nicotine delivery systems and age of asthma onset among US adults and youths. JAMA Netw. Open 7, e2410740 (2024).

    PubMed  PubMed Central  Google Scholar 

  41. GBD 2021 Diseases and Injuries Collaborators Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 403, 2133–2161 (2024).

    Google Scholar 

  42. Shin, Y. H. et al. Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Allergy 78, 2232–2254 (2023).

    CAS  PubMed  Google Scholar 

  43. Patwardhan, V. et al. Differences across the lifespan between females and males in the top 20 causes of disease burden globally: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Public Health 9, e282–e294 (2024).

    PubMed  PubMed Central  Google Scholar 

  44. Kim, S. et al. Global, regional, and national trends in drug use disorder mortality rates across 73 countries from 1990 to 2021, with projections up to 2040: a global time-series analysis and modelling study. eClinicalMedicine 79, 102985 (2025).

    PubMed  Google Scholar 

  45. Wang, H. et al. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21. Lancet 399, 1513–1536 (2022).

    CAS  Google Scholar 

  46. Lee, S. et al. Global, regional, and national trends in maternal mortality ratio across 37 high income countries from 1990 to2021, with projections up to 2050: a comprehensive analysis from the WHO Mortality Database. J. Korean Med. Sci. 40, e85 (2025).

    PubMed  PubMed Central  Google Scholar 

  47. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392, 1789–1858 (2018).

    Google Scholar 

  48. Institute for Health Metrics and Evaluation (IHME) Global Burden of Disease Study 2021 (GBD 2021) Socio-Demographic Index (SDI) 1950–2021 (IHME, 2024).

Download references

Acknowledgements

This study was funded by the Gates Foundation, Australian National Health and Medical Research Council, and Queensland Department of Health, Australia. This work was supported by the Yonsei Fellowship, funded by Lee Youn Jae (J.I.S.). This research was supported by the Ministry of Science and ICT (RS-2024-00509257 and IITP-2024-RS-2024-00438239 to D.K.Y.) and the Ministry of Health & Welfare (RS-2025-02220492 to D.K.Y.), Republic of Korea. The funder of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report. All authors had full access to the study data and had final responsibility for the decision to submit for publication.

Author information

Authors and Affiliations

Authors

Consortia

Contributions

J.O., S. Kim, Y. Yim, M.S.K., S.I.H., J.I.S. and D.K.Y. conceptualized and designed the study. These authors also developed the methodology and acquired the data. J.O., S. Kim, Y. Yim, M.S.K., S.I.H., J.I.S. and D.K.Y. conducted the statistical analysis and curated the data. S.I.H., J.I.S. and D.K.Y. validated the findings, interpreted the data and created the visualizations. They also managed the estimation or publications process. J.O., S. Kim and Y. Yim prepared the original draft. All authors reviewed and edited the paper and provided critical revisions. S.I.H., J.I.S. and D.K.Y. supervised the work and oversaw project administration. These same authors secured the funding. Contributions by the GBD 2023 Global Chronic Respiratory Disease and COVID Collaborators are described in the Supplementary Information.

Corresponding authors

Correspondence to Jae Il Shin or Dong Keon Yon.

Ethics declarations

Competing interests

S. Ansari reports grants or contracts from the Australian Government Department of Health Medical Research Future Fund and Royal Australian College of General Practitioners (payment made to UNSW Sydney, administering institution for the grants); payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Asthma Australia toward participation in the Quality Use of Medicines for Chronic Airways Disease Program funded by the Australian Government Department of Health and Honoraria from the National Health and Medical Research Council for participation in two Grant Assessment Committees for the Australian Government Department of Health; support for attending meetings and/or travel from Asthma Australia toward participation in the Quality Use of Medicines for Chronic Airways Disease Program design thinking workshop in Brisbane, Australia; and other support from UNSW Sydney through two Australian Government Medical Research Future Fund grants, outside the submitted work. A. Min reports patents planned, issued or pending: US20200253891A1 Method of Liver Cancer Treatment with Safranal-Based Formulations (Pending); US20200254049A1 Combination Therapy for Cancer (Pending); and US20200253890A1 Suppression and Inhibition of CDC25B with Safranal-Based Formulations (Pending), outside the submitted work. R. Ancuceanu reports consulting fees from AbbVie and Merck Romania; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AbbVie, Laropharm, Reckitt and Merck Romania; and support for attending meetings and/or travel from Merck Romania and Reckitt, outside the submitted work. J. A. Al-Tawfiq reports leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as a member of the executive board of the International Society for Infectious Diseases, outside the submitted work. M. Asghariahmadabad reports support for attending meetings and/or travel from the ASNR member in training travel grant to attend ASNR 2025, outside the submitted work. E.F.A. reports support for the present manuscript from the following grants: NIH/NHLBI K23 HL129888, Fred Hutch/UW CFAR AI027757 and NIH/NHLBI R03 HL160251 (all grant funding payments made to institution). M. Ausloos reports support for the present manuscript from the project ‘A better understanding of socio-economic systems using quantitative methods from physics’ funded by European Union—NextgenerationEU and Romanian Government, under National Recovery and Resilience Plan for Romania, contract no. 760034/23.05.2023, code PNRR-C9-I8-CF 255/29.11.2022, through the Romanian Ministry of Research, Innovation and Digitalization, within Component 9, ‘Investment I8’. A. Beloukas reports grants or contracts from Gilead (Research Grant and Sponsorship to the University of West Attica) and GSK/ViiV (Research Grant and Sponsorship to the University of West Attica); payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Gilead and GSK (paid to the University of West Attica); support for attending meetings and/or travel from Gilead and GSK (paid to the University of West Attica); and receipt of equipment, materials, drugs, medical writing, gifts or other services from Cepheid, outside the submitted work. E.J.B. reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from the Korean Diabetes Association, International Society for the Diabetic Foot, Diabetes Association of the R.O.C. (Taiwan) and the American Diabetes Association and support for attending meetings and/or travel from Korean Diabetes Association, Diabetes Association of the R.O.C. (Taiwan) and the International Society for the Diabetic Foot, outside the submitted work. P.J.G.B. reports the following patents planned, issued or pending: WO2020229805A1, BR112021022592A2, EP3965809A1, OA1202100511, US2023173050A1, EP4265271A2, EP4275700A2, outside the submitted work. A.J.C. reports support for the present manuscript from the Health Effects Institute. J.C. reports grants or contracts from the European Research Council Starting Grant (ERC-StG-2019-848325) and patents planned, issued or pending SURFACTANT-BASED HYDROGEL, METHODS AND USES THEREOF (Universidade Nova de Lisboa), outside the submitted work. N.C.-M. reports consulting fees from Signant Health outside the submitted work. X.D. reports support for the present manuscript from the Institute for Health Metrics and Evaluation, University of Washington. A. Faro reports support for the present manuscript from the National Council for Scientific and Technological Development, CNPq, Brazil, Researcher Grant (Bolsa Produtividade). R.F.G. reports other support from Elsevier as an associate editor outside the submitted work. Z. Guan reports grants or contracts from Dementia Centre of Excellence, Curtin enAble Institute and Curtin University outside the submitted work. I.M.I. reports support for the present manuscript from Ministry of Science, Technological Development and Innovation of the Republic of Serbia (no. 451-03-137/2025-03/200110). M.D.I. reports support for the present manuscript from Ministry of Science, Technological Development and Innovation of the Republic of Serbia (no. 451-03-47/2023-01/200111). N.E.I. reports leadership or fiduciary role in other board, society, committee or advocacy group, unpaid as The Bursar and Council Member of Malaysian Academy of Pharmacy and as Committee Member of Education Chapter, Malaysian Pharmacists Society, outside the submitted work. T. Joo reports support for the present manuscript from the National Research, Development and Innovation Office in Hungary (RRF-2.3.1-21-2022-00006, Data-Driven Health Division of National Laboratory for Health Security). M. Kivimaki reports grants or contracts from the Wellcome Trust (221854/Z/20/Z), the UK Medical Research Council (MR/Y014154/1), the National Institute on Aging (National Institutes of Health grants R01AG056477 and R01AG062553) and the Research Council of Finland (350426) outside the submitted work. K. Krishan reports non-financial support from the UGC Centre of Advanced Study, CAS II, awarded to the Department of Anthropology, Panjab University (Chandigarh, India) outside the submitted work. M.-C.L. reports support for the present manuscript from the National Science and Technology Council, Taiwan (NSTC 113-2314-B-003-002), and leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as technical editor, Journal of the American Heart Association, outside the submitted work. G. Liu reports grants or contracts from Al & Val Rosenstrauss Fellowship from Rebecca L. Cooper Medical Research Foundation, Australia, outside the submitted work. J. Liu reports support for the present manuscript from the National Natural Science Foundation (grant 72122001). A. Malinovschi reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Boehringer Ingelheim and Chiesi and receipt of sensors for exhaled nitric oxide measurements from NIOX in an investigator-initiated study from Uppsala University outside the submitted work. H. R. Marateb reports grants or contracts from The Beatriu de Pinós postdoctoral program from the Office of the Secretary of Universities and Research from the Ministry of Business and Knowledge of the Government of Catalonia program: 2020 BP 00261, and by the LLavor A grant, funded by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya, under the Programa Indústria del Coneixement: PREPARE (2024 LLAV 00083), outside the submitted work. S. Martini reports leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid from the Indonesian Public Health Association, outside the submitted work. A.G.M. reports consulting fees from Sanofi; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from GlaxoSmithKline; leadership or fiduciary role in other board, society, committee or advocacy group, unpaid as chair, European Respiratory Society (ERS) Airway Diseases Pharmacology and Treatment Group (5.1); stock or stock options in Health Networks; and other non-financial support from Verona Pharma, outside the submitted work. R. J. Maude reports support for the present manuscript from Wellcome Trust (grant number 220211). A.-F.A.M. reports grants or contract funding from ‘MilkSafe: A novel pipeline to enrich formula milk using omics technologies’, a research cofinanced by the European Regional Development Fund of the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH - CREATE - INNOVATE (project code: T2EDK-02222), as well as from ELIDEK (Hellenic Foundation for Research and Innovation, MIMS-860) (both outside of the present manuscript); payment for expert testimony as an external peer-reviewer for Fondazione Cariplo, Italy; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as editorial board member for Systematic Reviews and Annals of Epidemiology and as associate editor for Translational Psychiatry; stocks on a family winery; and other support from having been a senior scientific officer at BGI Group (Shenzhen, China), outside the submitted work. L. Monasta reports support for the present manuscript from the Italian Ministry of Health (Ricerca Corrente 34/2017) and payments made to the Institute for Maternal and Child Health IRCCS Burlo Garofolo. L. Muccioli reports support for attending meetings and/or travel from Jazz Pharma and Angelini, outside the submitted work. S. Nomura reports support for the present manuscript from grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (24H00663) and Precursory Research for Embryonic Science and Technology from the Japan Science and Technology Agency (JPMJPR22R8). B.O. reports grants or contracts from the Ministry of Research, Innovation and Digitization, project PNRR-I8 no. 842027778, contract no. 760096, outside the submitted work. A. Ortiz reports grants from Sanofi to institution IIS-FJD UAM and to Universidad Autonoma de Madrid (UAM); consulting fees from Astellas, AstraZeneca, Bioporto, Boehringer Ingelheim, Fresenius Medical Care, GSK, Bayer, Sanofi-Genzyme, Lilly, Chiesi, Otsuka, Novo Nordisk and Sysmex; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Astellas, AstraZeneca, Bioporto, Boehringer Ingelheim, Fresenius Medical Care, GSK, Bayer, Sanofi-Genzyme, Sobi, Menarini, Lilly, Chiesi, Otsuka, Novo Nordisk, Sysmex and Vifor Fresenius Medical Care Renal Pharma and Spafarma; support for attending meetings and/or travel from Astellas, AstraZeneca, Fresenius Medical Care, Boehringer Ingelheim, Bayer, Sanofi-Genzyme, Chiesi, Sobi and Bayer; participation on a Data Safety Monitoring Board or Advisory Board from Astellas, AstraZeneca, Boehringer Ingelheim, Fresenius Medical Care, Bayer, Sanofi-Genzyme, Chiesi, Otsuka, Novo Nordisk and Sysmex; and leadership or fiduciary role in other board, society, committee or advocacy group, unpaid as Council ERA SOMANE, outside the submitted work. R.P. reports participation on a Data Safety Monitoring Board or Advisory Board as a member of the Data Safety Monitoring Board dello studio ‘Consolidation with ADCT-402 (loncastuximab tesirine) after immunochemotherapy: a phase II study in BTKi-treated/ineligible Relapse/Refractory Mantle Cell Lymphoma (MCL) patients’—FIL, Fondazione Italiana Linfomi, Alessandria; leadership or fiduciary role in other board, society, committee or advocacy group, unpaid as a member of the EBMT Statistical Committee, European Society for Blood and Marrow Transplantation, Paris (F), and as a past member 2020–2023 (biostatistician) of the IRB/IEC Comitato Etico AO SS. Antonio e Biagio Alessandria-ASL AL-VC; outside the submitted work. V.C.F.P. reports grants or contracts from Sanofi Consumer Healthcare to conduct research on self-care in the Philippines and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from the Zuellig Family Foundation to write papers on health systems strengthening, outside the submitted work. M.J.P. reports stock or stocks options from Health-Ecore and PAG BV, outside the submitted work. L. Ronfani reports support for the present manuscript from the Italian Ministry of Health (Ricerca Corrente 34/2017) and payments made to the Institute for Maternal and Child Health IRCCS Burlo Garofolo. L.F.R. reports grants or contracts from GSK, MSK and Pfizer; consulting fees from GSK; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from GSK; and support for attending meetings and/or travel from GSK and Pfizer, outside the submitted work. B. Sartorius reports grants or contracts from the Australian National Health and Medical Research Council Fellowship (grant number 2034827), outside the submitted work. B.M.S. reports grants or contracts from Else Kröner-Fresenius Foundation Research Grant, Deutsche Forschungsgemeinschaft Research Grant and PharmaCept GmbH research grant; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca; and support for attending meetings and/or travel from Bayer AG, outside the submitted work. V. Sharma reports other support from DFSS (MHA)’s research project (DFSS28(1)2019/EMR/6) at Institute of Forensic Science & Criminology, Panjab University (Chandigarh, India), outside the submitted work. J.I.S. reports other financial or non-financial interests from Yonsei Fellowship, funded by Lee Youn Jae (JIS), outside the submitted work. L.M.L.R.S. reports grants or contracts with SPRINT, Sport Physical Activity and Health Research & Innovation Center, Polytechnic of Guarda, 6300-559 6 Guarda, Portugal, and collaborations with RISE–UBI, Health Sciences Research Centre, University of Beira Interior (6201-506 Covilhã, Portugal), outside the submitted work. J.A.S. reports consulting fees from ROMTech, Atheneum, Clearview healthcare partners, American College of Rheumatology, Yale, Hulio, Horizon Pharmaceuticals, DINORA, ANI/Exeltis, Frictionless Solutions, Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications and the National Institutes of Health; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events as a member of the speaker’s bureau of Simply Speaking; support for attending meetings and/or travel as a past steering committee member of OMERACT; participation on a Data Safety Monitoring Board or Advisory Board from the FDA Arthritis Advisory Committee; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as a past steering committee member of the OMERACT (an international organization that develops measures for clinical trials and receives arm’s length funding from 12 pharmaceutical companies); stock or stock options in Atai Life Sciences, Kintara Therapeutics, Intelligent Bio Solutions, Acumen Pharmaceuticals, TPT Global Tech, Vaxart Inc., Aytu BioPharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics, Seres Therapeutics, Tonix Pharmaceuticals Holding Corp., Abeona Therapeutics and Charlotte’s Web Holdings; and previously owned stock options in Amarin, Viking and Moderna, outside the submitted work. J.B.S. reports pharmaceutical company grants from 2021 to 2025 from Chiesi, GSK, Linde and Novartis via Hospital Universitario de La Princesa and participated in speaking activities, advisory committees and consultancies from 2021 to 2025 sponsored by Air Liquide, Almirall, AstraZeneca, Boehringer Ingelheim, CHEST, Chiesi, CNPT, ERS, FTH, Gebro, Grifols, GSK, IHME, Laminar Pharma, Linde, Lipopharma, Menarini, Mundipharma, Novartis, OMS/WHO, Pfizer, ResApp, RiRL, ROVI, SEPAR, Seqirus, WHO EUR, Takeda and Zambon. J.S.B. did not receive funding, directly or indirectly, from tobacco manufacturers or their affiliates. I.N.S. reports leadership or fiduciary role in other board, society, committee or advocacy group, unpaid as Trustee of the Citizens Advice Bureau for Hull & East Riding, United Kingdom, outside the submitted work. S.J.T. reports grants or contracts from Jazz Pharmaceuticals related to reviewing the impact of medicinal cannabis on patients with the epilepsy syndromes Lennox-Gastaut syndrome and Dravet syndrome and the 2023 Adult Psychiatric Morbidity Survey team, collecting epidemiological data on community-based adults living in England. This is a contracted study from NHS Digital, via the Department of Health and Social Care; the National Institute for Health and Care Research related to reviewing a national training program for health and social care professionals relating to learning disability and autism (all paid to the University of Leicester); and leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as academic secretary for the Neurodevelopmental Psychiatry Special Interest Group and Psychiatry of Intellectual Disability Faculty at the Royal College of Psychiatrists, editorial board member for Progress in Neurology and Psychiatry, Advances in Mental Health and Intellectual Disabilities, Advances in Autism and BMC Psychiatry, and editor of Psychiatry of Intellectual Disability Across Cultures (Oxford University Press), outside the submitted work. E.U. reports the following published patents, that is, A system and method of reusable filters for anti-pollution mask, A system and method for electricity generation through crop stubble by using microbial fuel cells, A system for disposed personal protection equipment (PPE) into biofuel through pyrolysis and method, A novel herbal pharmaceutical aid for formulation of gel and method thereof, and Herbal drug formulation for treating lung tissue degenerated by particulate matter exposure, and the filed patent, that is, A method to transform cow dung into the wall paint by using natural materials and composition thereof, and reports leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as executive council member, Indian Meteorological Society (Jaipur Chapter, India), and member secretary of DST PURSE Program, outside the submitted work. P.W. reports consulting fees from Novartis Pharmaceuticals outside the submitted work. Y. Yasufuku reports grants or contracts from Shionogi outside the submitted work. M. Zielińska reports other financial support as an Alexion, AstraZeneca Rare Disease, employee outside the submitted work. The other authors declare no competing interests.

Peer review

Peer review information

Nature Medicine thanks Atul Malhotra, Feng Sha, Ting Yang and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: Ming Yang, in collaboration with the Nature Medicine team.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

Extended Data Fig. 1 World map of age-standardized prevalence (A) and death rates (C) of chronic respiratory disease in 2023 and percentage change (B, D) from 1990 to 2023.

The figure displays the worldwide age-standardized prevalence rate (A) and death rate (per 100,000 population) (C) of chronic respiratory diseases in 2023, alongside the respective change rates in prevalence (B) and death (D) from 1990 to 2023. The color gradient, ranging from dark purple (high value) to pale yellow (low value), indicates the magnitude of each metric. The small insets beneath the main map provide magnified views of the Caribbean and Central America, the Persian Gulf, the Balkan Peninsula, Southeast Asia, West Africa, the Eastern Mediterranean, and Northern Europe.

Extended Data Fig. 2 World map of age-standardized prevalence rates for COPD (A, B) and asthma (C, D) in 2023 and percentage change from 1990 to 2023.

Abbreviation: COPD, chronic obstructive pulmonary disease. The figure displays the worldwide age-standardized prevalence rate (per 100,000 population) of COPD (A) and asthma (C) in 2023, alongside the respective change rates of COPD (B) and asthma (D) in prevalence from 1990 to 2023. The color gradient, ranging from dark blue or red (high value) to pale yellow (low value), indicates the magnitude of each metric. The small insets beneath the main map provide magnified views of the Caribbean and Central America, the Persian Gulf, the Balkan Peninsula, Southeast Asia, West Africa, the Eastern Mediterranean, and Northern Europe.

Extended Data Fig. 3 World map of age-standardized prevalence rates for pneumoconiosis (A, B) and interstitial lung diseases and pulmonary sarcoidosis (C, D) in 2023 and percentage change from 1990 to 2023.

The figure displays the worldwide age-standardized prevalence rate (per 100,000 population) of pneumoconiosis (A) and interstitial lung diseases and pulmonary sarcoidosis (C) in 2023, alongside the respective change rates of pneumoconiosis (B) and interstitial lung diseases and pulmonary sarcoidosis (D) in prevalence from 1990 to 2023. The color gradient, ranging from dark purple or green (high value) to pale yellow (low value), indicates the magnitude of each metric. The small insets beneath the main map provide magnified views of the Caribbean and Central America, the Persian Gulf, the Balkan Peninsula, Southeast Asia, West Africa, the Eastern Mediterranean, and Northern Europe.

Extended Data Fig. 4 World map of age-standardized death rates for COPD (A, B) and asthma (C, D) in 2023 and percentage change from 1990 to 2023.

Abbreviation: COPD, chronic obstructive pulmonary disease. The figure displays the worldwide age-standardized death rate (per 100,000 population) of COPD (A) and asthma (C) in 2023, alongside the respective change rates of COPD (B) and asthma (D) in prevalence from 1990 to 2023. The color gradient, ranging from dark blue or red (high value) to pale yellow (low value), indicates the magnitude of each metric. The small insets beneath the main map provide magnified views of the Caribbean and Central America, the Persian Gulf, the Balkan Peninsula, Southeast Asia, West Africa, the Eastern Mediterranean, and Northern Europe.

Extended Data Fig. 5 World map of age-standardized death rates for pneumoconiosis (A, B) and interstitial lung diseases and pulmonary sarcoidosis (C, D) in 2023 and percentage change from 1990 to 2023.

The figure displays the worldwide age-standardized death rate (per 100,000 population) of pneumoconiosis (A) and interstitial lung diseases and pulmonary sarcoidosis (C) in 2023, alongside the respective change rates of pneumoconiosis (B) and interstitial lung diseases and pulmonary sarcoidosis (D) in prevalence from 1990 to 2023. The color gradient, ranging from dark purple or green (high value) to pale yellow (low value), indicates the magnitude of each metric. The small insets beneath the main map provide magnified views of the Caribbean and Central America, the Persian Gulf, the Balkan Peninsula, Southeast Asia, West Africa, the Eastern Mediterranean, and Northern Europe.

Extended Data Fig. 6 Global age-sex-specific COPD (A), asthma (B), pneumoconiosis (C), ILD and pulmonary sarcoidosis (D) prevalence rates, 1990–2023.

Abbreviation: COPD, chronic obstructive pulmonary disease; ILD, interstitial lung disease. The figure presents the 1990–2023 global age- and sex-specific prevalence rate trends for COPD (A), asthma (B), pneumoconiosis (C), and ILD and pulmonary sarcoidosis (D). Blue indicates male, and pink indicates female. The bold line represents the mean prevalence rate (derived from the GBD 2023 draws), and the lighter shading denotes the 95% uncertainty interval (UI). For age groups whose trends are not clearly visible due to y-axis scaling, inset figures are provided. These data are population-level estimates (no separate biological or technical replicates), and the unit of study is the entire population in each region-year. No control group was used, as this is an observational, population-based analysis.

Extended Data Fig. 7 Global age-sex distribution of COPD (A), asthma (B), pneumoconiosis (C), and interstitial lung diseases (ILD) and pulmonary sarcoidosis (D) prevalence rates in 2023.

Abbreviation: COPD, chronic obstructive pulmonary disease; ILD, interstitial lung disease. The figure presents the 2023 global age- and sex-specific prevalence rates (per 100,000 population) of COPD (A), asthma (B), pneumoconiosis (C), and interstitial lung diseases and pulmonary sarcoidosis (D). Each bar represents the mean prevalence rate derived from the GBD 2023 draws for each region, with the thin black lines indicating the 95% uncertainty intervals (UI). Blue bars represent males, pink bars represent females. These estimates are population-level data (no separate biological or technical replicates), and the unit of study is the entire population in each region. No control group was used, as this is an observational, population-based analysis.

Extended Data Fig. 8 Global age-sex distribution of COPD (A), asthma (B), pneumoconiosis (C), and interstitial lung diseases (ILD) and pulmonary sarcoidosis (D) death rates in 2023.

Abbreviation: COPD, chronic obstructive pulmonary disease; ILD, interstitial lung diseases. The figure presents the 2023 global age- and sex-specific death rates (per 100,000 population) of COPD (A), asthma (B), pneumoconiosis (C), and interstitial lung diseases and pulmonary sarcoidosis (D). Each bar represents the mean death rate derived from the GBD 2023 draws for each region, with the thin black lines indicating the 95% uncertainty intervals (UI). Blue bars represent males, and pink bars represent females. These estimates are population-level data (no separate biological or technical replicates), and the unit of study is the entire population in each region. No control group was used, as this is an observational, population-based analysis.

Extended Data Fig. 9 AAPC of age-standardized incidence and death rates for chronic respiratory diseases by GBD region during the pre-COVID-19 (2010–2019) and the pandemic period (2020–2023).

The figure presents the average annual percentage changes in age-standardized incidence and death rates (per 100,000 population) of CRDs by GBD region for the pre-COVID-19 period (2010–2019) and the pandemic period (2020–2023). Purple bars represent the pre-pandemic period (2010–2019), and green bars represent the pandemic period (2020–2023).

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oh, J., Kim, S., Yim, Y. et al. Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990–2023: a Global Burden of Disease study. Nat Med 32, 197–223 (2026). https://doi.org/10.1038/s41591-025-04077-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41591-025-04077-9

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing